MedTrace Logo

Long Term Implications of Rare Brain Tumours'

NCT04708548 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 267

Last updated 2023-05-15

No results posted yet for this study

Summary

Patients diagnosed with oligodendroglioma with a specific molecular profile represent rare tumour groups (about 10% of adult gliomas) with relatively favourable prognosis (median survival between 8 and 12 years). These patients are often treated with surgery, chemotherapy and/or radiotherapy. However, as patients live for a long period of time, they may also experience long-term toxic side-effects of treatment. The long-term consequences of treatment- and disease-related factors on quality of life and cognitive functioning of these patients are largely unknown. This study aims to investigate quality of life and cognitive functioning in long-term survivors of oligodendroglioma (with IDH mutation and 1p/19q codeletion). This knowledge can support health care professionals prepare patients for any long-term consequences of treatment.

Conditions

  • Quality of Life
  • Cognitive Impairment
  • WHO Grade II Oligodendroglial Tumor
  • WHO Grade III Oligodendroglial Tumor
  • Long-term Effects of Cancer Treatment
  • Health-related Quality of Life

Interventions

OTHER

Health-related Quality of Life

Health-related quality of life (HRQOL) is an individual's or a group's perceived physical and mental health over time.

OTHER

Psychological Distress

Measured of the distress experienced by patients

OTHER

Fatigue

Measure of the extreme tiredness resulting from mental or physical exertion or illness

OTHER

Cognitive Functioning

Cognitive functioning refers to multiple mental abilities, including learning, thinking, reasoning, remembering, problem solving, decision making, and attention. This will be measured through self-report and cognitive testing.

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    collaborator NETWORK

  • The Leeds Teaching Hospitals NHS Trust

    collaborator OTHER

  • Galina Velikova

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-29
Primary Completion
2023-02-28
Completion
2023-02-28

Countries

  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04708548 on ClinicalTrials.gov